Fv-LDP-D3

Fv-LDP-D3 is a recombinant fusion protein designed for targeted cancer therapy, particularly for EGFR-overexpressing tumors such as esophageal and colorectal cancer. It is composed of the single-chain variable fragment (Fv) of an anti-EGFR antibody, the apoprotein of lidamycin (LDP), and domain III of human serum albumin (D3). Fv-LDP-D3 binds specifically to EGFR, is internalized via macropinocytosis, inhibits EGFR phosphorylation, downregulates inosine monophosphate dehydrogenase type II (IMPDH2), suppresses cell proliferation, and induces apoptosis in tumor cells. The addition of the D3 domain intensifies tumor uptake and tumor retention. It has demonstrated preclinical efficacy in animal models against esophageal and colorectal cancer, functioning as a tumor-targeted delivery platform[1][4][7][8].

Brand names

Fv-LDP-D3Fv-LDP-D-3Fv-LDP-D 3

Other names

Fv-LDP-D3Fv-LDP-D-3Fv-LDP-D 3